Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Bullboard Posts
Comment by fishbeeceeon Jun 28, 2017 2:15pm
177 Views
Post# 26415043

RE:RESULTS NOT OUTSTANDING

RE:RESULTS NOT OUTSTANDING
This stock currently trades at 5 times sales. Sales for 2017 are 6.2Mill. At 5 times sales gives a share price of $.35.
They are forcasting sales of 8.3 million without including to recent releases. If those new releases reach 15 % of the companies four year sales goal for 2018 then I could a share price of $.55, with sales at 10.1 million and still trading at 5 times sales.

You say,

I'm sorry but this is going to be quite a while before any major increase in SP. No need to buy more now, it's not going anywhere. A loss is a loss, needs to be profitable. It also needs new products while the present ones grow.

That logic shows that most of the news release was missed by you as a huge increase in sales and it has products in the approval pipeline and is all cashed up for an aquisition.
Bullboard Posts